Eye Institute, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Medicine (Baltimore). 2024 Jun 7;103(23):e37584. doi: 10.1097/MD.0000000000037584.
To evaluate the clinical effects between dexamethasone and triamcinolone acetonide (TA) after phacoemulsification and intraocular lens implantation among cataract patients.
Pubmed, Embase, and the Cochrane Library were searched for studies published up to August 2020. The primary outcome was intraocular pressure. The secondary outcomes were the logarithm of the minimum angle of resolution (logMAR), anterior chamber cell, and anterior chamber flare. The pooled effect sizes were expressed as weighted mean differences (WMDs) or standardized mean differences (SMDs) of 95% confidence intervals (95% CIs). Cochrane Collaboration risk of bias tool and Newcastle-Ottawa scale criteria were used for the quality assessment of included studies.
Seven relevant studies met the inclusion criteria. For the primary outcome, there was no significant difference between TA injection and dexamethasone in comparing intraocular pressure (IOP) (SMD = 0.22, 95% confidence interval [CI] [-0.29, 0.73], P = .408; I² = 86.9%) in the first day after treatment and last day of assessment. For the secondary outcomes, the logMAR (WMD = 0.01, 95% CI [-0.06, 0.08]) and the anterior chamber flare (SMD = 0.08, 95% CI [-0.01, 0.18], P = .087; I² = 0%) showed no differences. However, the amount of anterior chamber cells (SMD = -0.21, 95% CI [-0.42, -0.01], P = .044; I² = 0%) in the TA injection on the first day postoperative was higher than for dexamethasone. After treatment, there was no difference between the 2 groups.
This study supports that there were no differences in IOP, logMAR, and anterior chamber flare between TA injection and dexamethasone among cataract patients. TA injection treatment on the first day showed higher amounts of anterior chamber cells than with dexamethasone.
评估白内障患者超声乳化白内障吸除术后应用地塞米松与曲安奈德(TA)的临床效果。
检索 Pubmed、Embase 和 Cochrane Library 数据库,截至 2020 年 8 月的研究。主要结局指标为眼压。次要结局指标为最小分辨角对数(logMAR)、前房细胞和前房闪辉。汇总效应量表示为 95%置信区间(95%CI)的加权均数差(WMD)或标准化均数差(SMD)。采用 Cochrane 协作偏倚风险工具和纽卡斯尔-渥太华量表评价纳入研究的质量。
7 项相关研究符合纳入标准。对于主要结局,治疗后第 1 天和最后评估日,TA 注射组与地塞米松组的眼压(SMD=0.22,95%CI[-0.29,0.73],P=0.408;I²=86.9%)无显著差异。对于次要结局,logMAR(WMD=0.01,95%CI[-0.06,0.08])和前房闪辉(SMD=0.08,95%CI[-0.01,0.18],P=0.087;I²=0%)无差异。然而,术后第 1 天 TA 注射组的前房细胞量(SMD=-0.21,95%CI[-0.42,-0.01],P=0.044;I²=0%)高于地塞米松组。治疗后,两组间无差异。
本研究支持白内障患者中,TA 注射与地塞米松在眼压、logMAR 和前房闪辉方面无差异。TA 注射在术后第 1 天表现出更高的前房细胞量。